Primer Tiroid Diffüz Büyük B Hücreli Lenfoma: Olgu Sunumu

Öz

Primer tiroid lenfoması, tüm tiroid malignitelerinin yaklaşık %5'ini ve ekstranodal lenfomaların %2'sinden azını oluşturan nadir bir malignitedir. Diffüz B hücreli lenfoma, Primer tiroid lenfomalarının en sık görülen patolojik alt tipidir. Tipik olarak hızla büyüyen, ağrısız bir tiroid kitlesi olarak ortaya çıkar ve bası semptomlarına neden olabilir. Tedavisi tiroid dışı lenfomalara bezer şekilde yapılmaktadır.

Anahtar Kelimeler

• Primer tiroid lenfoması
• diffüz büyük B hücreli lenfoma
• tedavi

Primary Thyroid Diffuse Large B Cell Lymphoma: Case Report

Öz

Primary thyroid lymphoma is a rare malignancy, accounting for approximately 5% of all thyroid malignancies and less than 2% of extranodal lymphomas. Diffuse B-cell lymphoma is the most common pathological subtype of primary thyroid lymphoma. It typically presents as a rapidly growing, painless thyroid mass and may cause compressive symptoms. Its treatment is similar to non-thyroid lymphoma.

Anahtar Kelimeler

• Primary thyroid lymphoma
• diffuse large B-cell lymphoma
• treatment

Kaynakça

1. 1. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375-2390.
2. 2. International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A Predictive Model for Aggressive Non-Hodgkin’s Lymphoma. New England Journal of Medicine. 1993;329(14):987-994.
3. 3. Møller MB, Pedersen NT, Christensen BE. Diffuse large B‐cell lymphoma: clinical implications of extranodal versus nodal presentation – a population‐based study of 1575 cases. Br J Haematol. 2004;124(2):151-159.
4. 4. Castillo JJ, Winer ES, Olszewski AJ. Sites of extranodal involvement are prognostic in patients with diffuse large B‐cell lymphoma in the rituximab era: An analysis of the Surveillance, Epidemiology and End Results database. Am J Hematol. 2014;89(3):310-314.
5. 5. Guastafierro S, Tedeschi A, Criscuolo C, et al. Primary Extranodal Non-Hodgkin’s Lymphoma of the Vagina: A Case Report and a Review of the Literature. Acta Haematol. 2012;128(1):33-38.
6. 6. Shikama N, Ikeda H, Nakamura S, et al. Localized aggressive non-Hodgkin’s lymphoma of the nasal cavity: a survey by the Japan Lymphoma Radiation Therapy Group. International Journal of Radiation Oncology*Biology*Physics. 2001;51(5):1228-1233.
7. 7. Domchek SM, Hecht JL, Fleming MD, Pinkus GS, Canellos GP. Lymphomas of the breast. Cancer. 2002;94(1):6-13.
8. 8. Ferrucci PF, Zucca E. Primary gastric lymphoma pathogenesis and treatment: what has changed over the past 10 years? Br J Haematol. 2007;136(4):521-538.

9. 9. Avilés A, Neri N, Huerta-Guzmán J. Large bowel lymphoma: An analysis of prognostic factors and therapy in 53 patients. J Surg Oncol. 2002;80(2):111-115.
10. 10. Güngör S, Vural Ö, Çerçi M. Primer Mide Lenfoması. Selçuk Tıp Dergisi. 1992;8(1):143-146.
11. 11. Demircioglu S, Telci U, Ozcelik M, Dogan A, Bayram İ. Renal involvement in diffuse large B-cell lymphoma: A case report. Marmara Medical Journal. 2019;32(3):144-146.
12. 12. Tekinalp A, Demircioğlu S, Karakuş V, Çeneli Ö, Turgut B. Yaygın Büyük B Hücreli Lenfoma (YBBHL) Tanılı Olguların Retrospektif Değerlendirmesi. Namık Kemal Tıp Dergisi. 2020;8(3):383-390.
13. 13. Pavlidis ET, Pavlidis TE. A Review of Primary Thyroid Lymphoma: Molecular Factors, Diagnosis and Management. Journal of Investigative Surgery. 2019;32(2):137-142.
14. 14. Derringer GA, Thompson LDR, Frommelt RA, Bijwaard KE, Heffess CS, Abbondanzo SL. Malignant lymphoma of the thyroid gland: a clinicopathologic study of 108 cases. Am J Surg Pathol. 2000;24(5):623-639.
15. 15. Graff-Baker A, Sosa JA, Roman SA. Primary thyroid lymphoma: a review of recent developments in diagnosis and histology-driven treatment. Curr Opin Oncol. 2010;22(1):17-22.
16. 16. Sharma A, Jasim S, Reading CC, et al. Clinical Presentation and Diagnostic Challenges of Thyroid Lymphoma: A Cohort Study. Thyroid. 2016;26(8):1061-1067.
17. 17. Travaglino A, Pace M, Varricchio S, et al. Clinical features associated with high pathological grade in primary thyroid lymphoma. Pathol Res Pract. 2020;216(3):152819.
18. 18. Watanabe N, Noh JY, Narimatsu H, et al. Clinicopathological features of 171 cases of primary thyroid lymphoma: a long‐term study involving 24 553 patients with Hashimoto’s disease. Br J Haematol. 2011;153(2):236-243.
19. 19. Katna R, Shet T, Sengar M, et al. Clinicopathologic study and outcome analysis of thyroid lymphomas: Experience from a tertiary cancer center. Head Neck. 2013;35(2):165-171.
20. 20. 20. Wei X, Li Y, Zhang S, Li X, Gao M. Evaluation of primary thyroid lymphoma by ultrasonography combined with contrast-enhanced ultrasonography: A pilot study. Indian J Cancer. 2015;52(4):546.
21. 21. Li XB, Ye ZX. Primary Thyroid Lymphoma: Multi-Slice Computed Tomography Findings. Asian Pacific Journal of Cancer Prevention. 2015;16(3):1135-1138.
22. 22. Hancock B. Primary thyroid lymphoma: The 40 year experience of a UK lymphoma treatment centre. Int J Oncol. Published online February 22, 2012.
23. 23. Graff-Baker A, Roman SA, Thomas DC, Udelsman R, Sosa JA. Prognosis of primary thyroid lymphoma: Demographic, clinical, and pathologic predictors of survival in 1,408 cases. Surgery. 2009;146(6):1105-1115.
24. 24. Derringer GA, Thompson LDR, Frommelt RA, Bijwaard KE, Heffess CS, Abbondanzo SL. Malignant Lymphoma of the Thyroid Gland. Am J Surg Pathol. 2000;24(5):623-639.
25. 25. Chai YJ, Hong JH, Koo DH, et al. Clinicopathological characteristics and treatment outcomes of 38 cases of primary thyroid lymphoma: a multicenter study. Ann Surg Treat Res. 2015;89(6):295.
26. 26. Mian M, Gaidano G, Conconi A, et al. High response rate and improvement of long-term survival with combined treatment modalities in patients with poor-risk primary thyroid diffuse large B-cell lymphoma: an International Extranodal Lymphoma Study Group and Intergruppo Italiano Linfomi study. Leuk Lymphoma. 2011;52(5):823-832.
27. 27. Dwyer, Mary. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ® ) B-Cell Lymphomas NCCN.Org NCCN Guidelines for Patients ® Available at Www.Nccn.Org/Patients.; 2024. www.nccn.org/patients